Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A<sub>2A</sub> Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS
The authors in the current work suggested the potential repurposing of omarigliptin (OMR) for neurodegenerative diseases based on three new findings that support the preliminary finding of crossing BBB after a single dose study in the literature. The first finding is the positive results of the dock...
Main Authors: | Bassam M. Ayoub, Haidy E. Michel, Shereen Mowaka, Moataz S. Hendy, Mariam M. Tadros |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/4/889 |
Similar Items
-
Enhanced Extraction Technique of Omarigliptin from Human Plasma—Applied to Biological Samples from Healthy Human Volunteers
by: Shereen Mowaka, et al.
Published: (2020-09-01) -
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
by: Sachiko Hattori, et al.
Published: (2021-03-01) -
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
by: Ling Li, et al.
Published: (2021-01-01) -
Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
by: Sachiko Hattori
Published: (2020-03-01) -
GLP-1 Receptor: A New Target for Sepsis
by: Fuxun Yang, et al.
Published: (2021-07-01)